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ABSTRACT
Mesenchymal stem cell (MSC) injections for osteoarthritis is reviewed.
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Methods: PubMed search was conducted to identify articles in English from 20032018 that used intra- articular injection (IA), cartilage repair, cartilage regeneration,
chondral injury, adipose stem cells, bone marrow stem cells, mesenchymal stem cells, or
autologous stem cells.
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RESULTS: 388 patients receiving IA MSC injections are discussed with data obtained
from 10 case reports or case series, 4 randomized clinical trials (RCT), 1 cohort study, and
3 case controlled therapeutic studies.
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Conclusions: MSC injections may be an effective adjunct in the management of
osteoarthritis and a variety of cartilage related pathologies.
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INTRODUCTION
Osteoarthritis (OA) is a degenerative disease of
diarthrodial joints characterized by loss of articular
cartilage, deformity, and pain. The two greatest
risk factors for OA are obesity and joint injury.1,2
Symptomatic OA is reported in 12% of American
adults, with as many as 37% of adults demonstrating
radiographic evidence of OA.3 OA is a growing
problem due to aging population, obesity epidemic,
and low intrinsic capacity for cartilage damage
repair. Mesenchymal stem cells (MSCs) can present
a novel paradigm to deal with the problem of tissue
regeneration, cartilage damage, and OA. Their
paracrine effect on surrounding tissue reduces
inflammatory responses with MSCs providing
regenerative cells to repair damaged cartilage.4 The
goal of this article is to provide a review of the use of
MSCs delivered directly to diarthrodial joints by intraarticular injections for orthopedic cartilage repair and
symptom relief.
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Numerous non-pharmacologic and pharmacologic
options are used for symptom management in
OA, but none of these strategies can improve the
structural damage that occurs with OA.5,6 Current
OA treatment recommendations by the American
Association of Orthopedic Surgeons (AAOS)
emphasize educational and physical therapy,
the use of acetaminophen and NSAID drugs, and
intra-articular corticosteroid injections.7 Their
recommendations regarding the use of growth factor
injections and/or platelet rich plasma (PRP) remain
inconclusive.7
Surgical management of OA involves different
degrees of invasive procedures with total joint
replacement being the most common and the most
invasive. Less invasive methods such as autologous
chondrocyte implantation (ACI) have data proven
benefit but an inability to correct large osteochondral
defects.8 Microfracture and arthroscopic debridement
of tissue also offer symptomatic benefit with success
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rates similar to other less invasive techniques
like autologous matrix induced chondrogenesis
(AMIC); however, microfracture and arthroscopic
debridement may result in the formation of
biomechanically inferior fibrocartilage.9 One main
goal of newer treatment of OA is the delivery or
induction of stem cells to produce true hyaline
cartilage.
The success seen using mesenchymal stem cell
therapy is rooted in the ability of MSCs to differentiate
into all mesodermal tissues, specifically cartilage,
bone, ligament, and tendon. They are also capable of
modulating functions of T and B cells and secreting a
variety of growth factors and cytokines like IL-10 and
IL-12p40, which are anti-inflammatory in function.10–12
This paracrine mechanism is thought to be a major
directing force to accelerate and direct tissue repair
by host derived cells.13 MSCs are thought to suppress
local immune response by producing cytokines and
prostaglandin E2, inhibiting fibrosis, and further
stimulating differentiation of stem cells.14,15 MSCs
have also demonstrated homing ability, specifically
incorporating into injured tissue and assisting the
healing of native tissues.16 Preclinical evidence has
shown that MSCs injected into animal models of
naturally occurring OA, enzyme-induced OA, and
post-traumatic OA may help to regenerate cartilage
lesions.17,18 The research using animal models and
comparisons of scaffold vs non-scaffold stem cell
application has also been well reviewed and detailed
previously.17, 19–21 These features make MSCs an
attractive strategy for OA management with MSC
isolation and delivery being critical to clinical success.
Traditionally, MSCs have been isolated from bone
marrow, typically from the iliac crest.22 Wakitani et
al. were the first to demonstrate the regenerative
use of MSCs for articular cartilage repair in humans
by surgically implanting culture-expanded bone
marrow MSCs.23 Bone marrow- mesenchymal
stem cells (BM-MSCs) have been widely studied
but carry the morbidity associated with donor site
pain and infection. However, in the past decade,
multiple sources including adipose tissue, synovium,
periosteum, umbilical cord blood, and peripheral
blood have also been studied. Key components
in selection of an appropriate MSC source include
the accessibility of the harvest tissue, stem cell
population density, and ease of cell differentiation,
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making adipose-derived stem cells (ADSCs) very
attractive.24–26 ADSCs have been demonstrated to
have similar differentiation capacity and morphology
to bone marrow derived cells.24 Although the
most chondrogenic and osteogenic source of
MSCs is synovium, ADSCs have chondrogenic and
osteogenic activity requiring minimal stimulation
by growth factors and cytokines.27–29 Augmentation,
especially with a co-injection of PRP, may be
beneficial.30
PRP is novel biologic scaffold that has been widely
used as a MSC carrier. PRP is non- immunogenic,
readily bio-absorbable, and easily prepared
in a perioperative setting, and thus meets the
major criteria as a MSC carrier.30 A double blind
prospective multi-center trial by Mishra et al. in 2013
demonstrated clinically meaningful improvement in
refractory tennis elbow treated with PRP.31
BONE MARROW CULTURE EXPANDED
MESENCHYMAL STEM CELLS
Bone marrow mesenchymal stem cells (BMMSCs) are the best characterized MSCs and have
osteogenic and chondrogenic potential that is
greater than that of ADSCs.27 These MSCs are a
reliable source for intra-articular injections and have
not been shown to increase risk of malignancy.32
The earliest reports of successful BM-MSC injection
therapy came in 2006 when Centeno et al. described
a case report of a male patient with a twenty year
history of hip pain and a diagnosis of OA. The
patient was treated with two intra-articular hip
injections of augmented BM-MSC one month apart.
BM-MSC concentrate was added to hyaluronic acid
and a thrombin activated platelet scaffold. The
first injection was estimated to contain < 100,000
BM-MSC and the second 300-400,000 BM-MSC. At
the time of the second injection, the patient had
no MRI evidence of improvement but reported
clinical improvement. At eight weeks post-injection,
evidence of increased joint space and neocortex
formation over the area of previous subchondral
cysts was reported. Walking distances and sitting
tolerances improved two levels as compared with
pre-injection scores.33 Additional case reports and
case studies have been reported (Table 1).
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TABLE 1. Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)
BMSC- Bone Marrow-Derived Stem Cells; OA- osteoarthritis; HA- hyaluronic acid; WOMAC- Western Ontario
and McMaster University Osteoarthritis Index; ICRS- International Cartilage Repair Society; ADL- Activities of
Daily Living; VAS- Visual Analog Scale; SF-36- Short Form Health Survey; MOCART- Magnetic Resonance Observation of Cartilage Repair Tissue
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In 2008, Centeno et al. published a case of knee OA
treated with a single injection of cultured BM-MSCs
(22.4 million) and a platelet lysate preparation. The
patient had follow-up injections of platelet lysate
one and two weeks after the first injection. Excellent
outcomes were reported with a decrease in visual
analog score (VAS) by 95% and magnetic resonance
imaging (MRI) evidence of increased cartilage
volume at three months post injection.34 In 2011, a
study by Davatchi et al. reported the results of four
patients with knee OA who were injected with 8x106
BM-MSCs and were evaluated one week after the
injection and then monthly for one year.35 Functional
assessments were made by walking time to pain,
stair climb number, and VAS. Three of the four
subjects reported an improvement in walking time
and stair climb capacity, and a 24-50% improvement
in VAS. No improvement was seen on x-ray at followup. In another study by Emadenin et al., 6 patients
with knee OA were injected with 24 million cultured
BM-MSCs with 12- month follow-up. Optimal results
were seen at 6 months as evaluated by VAS, Western
Ontario and McMaster University Osteoarthritis Index
(WOMAC), and walking distances. Importantly, pain
reduction and improvement in joint function were
also noted but decreased at one year. Three of the six
demonstrated increased thickening of the meniscus
on MRI at six months follow-up.36
In 2012, a study by Lee et al. examined the
effects of injecting BM-MSCs for seventy nonrandomized patients less than 55 years of age
with full thickness chondral lesions in a single
compartment of the knee. Thirty-five patients
received previously established treatment using
arthroscopic microfracture and arthroscopic
surgical implantation of MSC with periosteal flap
coverage. The other thirty-five received the same
arthroscopic microfracture followed by injection
of 10 million BM-MSCs then 2ml hyaluronic acid
(HA) in an outpatient clinic after surgery. Followup injections of HA (2ml) at two and four weeks
were also administered. Subjects were followed
for twenty-four months and evaluated using
International Cartilage Repair Society (ICRS) injury
evaluation package, Short Form Health Survey (SF36), International Knee Documentation Committee
(IKDC) subjective evaluation form, the Lysholm
knee scale, and the Tegner activity level scale.
A post-op MRI was also obtained. MRI results at
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one year showed neocartilage with good filling
and significant reduction in underlying marrow
edema. Improvement was seen in all patients, but
the injected group was reported to have superior
results according to the IKDC and Lysholm scores.
No difference was noted between the VAS and
the SF-36 score between the groups. As a result
of the excellent clinical outcomes, no second look
arthroscopies were performed.37
Varma et al. conducted a randomized controlled trial
(RCT) utilizing BM-MSC with fifty patients with mild
to moderate knee OA. Half were treated by injection
of buffy coated BM-MSC concentrate following
arthroscopic debridement and compared to
debridement alone. VAS and osteoarthritis outcome
scores (OAOS) were evaluated at one, two, three, and
six months follow-up. Significant improvement was
seen at six months for the stem cell group in VAS
(5.24 vs 2.12) and OAOS scores (56.57 vs 79.28).38
Wong et al. also conducted an RCT using BM-MSC
injections at the time of microfracture and high
tibial osteotomy (HTO) for twenty-eight patients,
and compared these results to twenty-eight patients
randomized to receive no MSC injection.39 At one
year follow-up, patients’ magnetic resonance
observation of cartilage repair tissue (MOCART)
scores were improved in the group receiving MSCs.
Patients in this group also reported statistically
significant improvement in Lysholm, Tegner, and
IKDC scores.
In 2013, a cohort of twelve patients with Kellgren
and Lawrence grade II-IV knee OA was injected with
40 million cultured BM-MSCs and followed for twelve
months. Evaluation by MRI T2 showed improvement
in cartilage, as well as significant clinical
improvement in functional scores and VAS.40 These
studies clearly demonstrate that optimal dosing of
MSC is not known with ranges from 100,000 to 40
million BM-MSCs used in the studies presented.
In 2014, Vangsness et al. published their results from
an RCT using BM-MSCs versus placebo injections
administered to fifty-five patients seven to ten days
after a partial medial meniscectomy.41 Patients
received injections of either 50x106 allogeneic BMMSCs, 150x106 MSCs, or a hyaluronic acid control.
The authors found increased meniscal volume on
MRI in both groups receiving MSCs, and significantly
increased VAS score improvement at one and two
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years in the MSC groups compared to the control
group.
ADIPOSE-DERIVED MESENCHYMAL STEM CELLS
(ADSCS)
A critical difference in studies using ADSCs versus
BM-MSCs is the near immediate injection of stem
cells following harvest; readily available reservoirs
include the buttock, abdominal, and infrapatellar
fat pads.26,30,42–45 Thus, adipose tissue is ideal for
same day harvest and injection, making it attractive
for traumatic injury cases. Recent studies using
ADSCs have covered a wider spectrum of chondral
related pathologies, including OA of the hip and
knee, osteonecrosis of the femoral head, and
osteochondral lesions of the talus (Table 2).
A case series published by Pak et al. in 2011
evaluated the safety and efficacy of concentrated
ADSCs in four patients.43 Two patients had stage IV
osteonecrosis of the femoral head and were given
intra-articular injections of ADSC concentrate mixed
with PRP, HA, and CaCl2. Subjects returned every
week for follow-up injection of PRP and CaCl2 for
a total of four injections. Two other subjects with
OA of the knee were injected with ADSC, PRP, and
CaCl2. They also had weekly injections of PRP and
low dose dexamethasone for four weeks. Patients
were seen in follow-up at three weeks and twelve
weeks. Pre-procedure evaluations included VAS, MRI,
and functional rating index. Repeat MRI at twelve
weeks showed bone regeneration of the femoral
heads and regeneration of the meniscus in the OA
patients. This study suggests that ADSCs may be
partially responsible for patients’ improvement.
In 2013, the same group published another case
series using ADSC intra-articular injections to treat
chondromalacia patellae in three patients.42 Each
was evaluated pre-procedurally with MRI and VAS
pain assessment. Low abdominal liposuction was
used to collect ADSC and cells were concentrated the
same day as injection. Sixteen million concentrated
ADSCs were injected into the retropatellar joint
space with PRP and HA. All patients returned on day
three, seven, fourteen, and twenty-eight for repeat
injections of PRP and HA with the day fourteen
injection including low dose dexamethasone.
Patients were seen for follow-up at three months,
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when MRI demonstrated cartilage-like tissue
regeneration, and subjects reported 80-90%
pain improvement. However, it should be noted
that despite these positive outcomes, there were
discrepancies in the authors’ reported protocol that
limit interpretation of this study.
In 2012, Koh et al. published a therapeutic case
series of twenty-five subjects to evaluate whether
percutaneous injection of ADSCs from the infrapatellar fat pad could improve clinical outcomes for
knee OA.30 Intra-articular injections of ADSCs (mean
1.9 million) in concert with PRP and arthroscopic
debridement were compared to a matched control
group without injections of stem cells. All patients
had follow-up injections of PRP on day seven and
fourteen. Pre- and post- operative evaluations
were performed using VAS, Lysholm, and Tegner
scores, and all revealed greater total improvement
when compared to the control group. Overall
outcomes were similar for pain relief and functional
improvement. Patients in this study were further
evaluated at two years by MRI, VAS, and scores for
WOMAC and WORMS. Interestingly, an improvement
of WOMAC scores, from 49.9 at 0-1 years to 30.3 at
1-2 years was observed. Possibly the most important
finding from the group was the correlation between
cell count at injection and patient outcomes.
Notably, there was also a positive correlation
between the dosage of ADSCs and improvement of
pain, function, and MRI findings.44
Another study assessing the effect of ADSCs
included thirty study patients and thirty-five control
patients with osteochondral (OCD) lesions of the
talus. All patients were over fifty years of age. This
study assessed the role of ADSCs in treating talar
OCD lesions in conjunction with marrow stimulation
vs. marrow stimulation alone. ADSCs were harvested
from the butt pad the day prior to treatment.
Outcomes were assessed using VAS, AOFAS score,
Roles and Maudsley score, and Tegner activity scale
over a mean of twenty-two months. Patient outcome
scores improved in both groups, and the authors
noted that patients with lesions larger than 109
mm2 or with subchondral cysts were likely to have
superior outcomes when treated with ADSCs.45
Recently, Spasovski et al. evaluated the clinical
and radiographic outcomes of a single injection
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TABLE 2. Adipose-Derived Mesenchymal Stem Cells (ADSCs)
ADSC- Adipose-Derived Stem Cells; OA- osteoarthritis; PRP- platelet rich plasma; HA- hyaluronic acid; WOMACWestern Ontario and McMaster University Osteoarthritis Index; VAS- Visual Analog Scale; AOFAS- American
Orthopaedic Foot and Ankle Society; KSS- Knee Society Score
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of ADSCs in nine patients with knee osteoarthritis.
The authors used a concentration of 0.5-1.0 x 107
cells. After eighteen months of follow-up, patients
reported improvement in VAS and knee society score
(KSS). Radiographs showed neither improvement nor
progression of degenerative changes.46
PERIPHERAL BLOOD STEM CELLS
Peripheral blood progenitor cells (PBPCs) are
easily obtained with both central and peripheral
intravenous access and have been successfully used
to treat international cartilage repair society (ICRS)
grade III-IV chondral knee lesions. The case series by
Saw et al. describes five subjects who were treated
with arthroscopic subchondral drilling followed by
five weekly injections of PBPCs mixed with HA.47
Second look arthroscopy demonstrated articular
cartilage regeneration with histologic sections
showing hyaline cartilage regeneration as the major
component of the repaired tissue. The success of

the case series prompted Saw et. al. to evaluate the
treatment process of five weekly injections of PBPCs
mixed with HA in an RCT of fity patients with ICRS
grade III-IV lesions randomized to either 1) those
treated with subchondral drilling and HA alone,
and 2) those treated with drilling followed by PBPCs
and HA (Table 3). Subjective IKDC scores and MRI
evaluations were made pre- and post-operatively on
all patients, and second look arthroscopy and biopsy
at eighteen months were taken from sixteen patients
in each group. There were no statistically significant
differences in IKDC scores. However, statistically
significant improvement was seen in both MRI
findings and ICRS II scores in the control group.
Furthermore, more type 2 collagen was identified in
the intervention group, as compared to “limited to
no” type 2 collagen in the control.48
In another case study of five patients who failed
conservative therapy for knee OA, arthroscopic
micro drilling was performed in all patients with
two subsequent IA injections of PBPCs with

TABLE 3. Peripheral Blood Mesenchymal Stem Cells (PBSCs)
PBSC- Peripheral blood stem cells; ; OA- osteoarthritis; HA- hyaluronic acid; WOMAC- Western
Ontario and McMaster University Osteoarthritis Index; ICRS- International Cartilage Repair Society;
IKDC- International Knee Documentation Committee; KOO- Knee Injury and Osteoarthritis Outcome
Scores
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growth factors and HA, repeated at days seven and
fourteen. Outcomes evaluated WOMAC and knee
injury and osteoarthritis outcome scores (KOO) at
baseline, one, and six months along with biopsy.
Significant improvements in WOMAC and KOO
scores were noted in all patients at one and six
months. Biopsy showed increased proteoglycan and
glycosaminoglycan content which suggested hyaline
cartilage formation (Table 3).49 PBPCs presents a less
invasive alternative to traditional BM-MSC and ADSC
harvest protocols.
DISCUSSION
Review of current research involving IA injection
of MSCs for various chondral-related pathologies
is promising. The rising interest in cartilage
regeneration is predictable considering the impact
that a successful regenerative treatment would
have on the field of orthopedics. However, our
knowledge of the process is still in the preliminary
stages. The vast majority of the publications on
stem cell injection therapy are preclinical, but
have shown great promise in animal models
and RCTs.8,15,17,18,21 Studies included in this review
demonstrate the diversity and limitations of current
research, especially relatively short patient followup and the variability in dosing regimens and use
of concomitant therapies. However, symptomatic
benefit and evidence of improvement on advanced
imaging were noted in many studies.
MSCs can be harvested from bone marrow, adipose
tissue, synovium, peripheral blood, umbilical cord
blood, muscle, skin, and periosteum; each donor
has a variable capacity to produce cartilage and
bone. Each of these sources also differs in the
relative ease or morbidity associated with harvesting
MSCs. Furthermore, the optimal number of stem
cells injected is far from certain. Although the
dose-dependent nature of cartilage regeneration
is still unknown, there is some evidence of a dosedependent effect.41,42 Of the groups reviewed, dosing
varied significantly with upwards of 40 million to
as few as 100,000 cells being used, making any
comparison between study outcomes difficult. The
proper dose for injection therapy is a key point that
needs to be clarified with future research. Finally,
although outside the scope of this paper, allogeneic
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BM-MSCs avoid the expensive and slow cell
expansion process used in autologous harvest, but
theoretically may cause host immune rejection; no
adverse reactions were identified in an RCT by Vega
et al. in 2015 examining 30 IA injections for knee
OA.50
Cellular and biochemical factors related to
chondrogenesis are other key developing areas of
research. Extensive in vitro work has been done
showing the growing characteristics and behavior
of ADSCs in recombinant BMP-2, TGF-β, PDGF and
in various biologic scaffolds like PRP.28,51–53 New
discoveries and better understanding of MSC
processes will continue to fuel advancements in the
field of chondral regeneration.
Limitations of MSCs for the treatment of OA must
also be considered. Long-term safety and efficacy of
these therapies has not been proven. In a review by
Peeters et al. of 844 injections with a mean followup of twenty-one months, the authors concluded
that applications of cultured stem cells in joints
appears safe.54 A follow-up study by Jo et al. in 2017
examined the two year outcomes of their eighteen
patients with knee OA who had received AD-MSC
injections, and found that the clinical outcomes for
low- and medium-dose groups deteriorated one year
after injections, while the high-dose group results
plateaued.55 Furthermore, patients with severe OA
have decreased proliferative capacity of patientderived MSCs which, in addition to the burden of
their advanced degeneration and deformity, limits
the utility of these therapies in many patients.56
With longer follow-up and further studies, we will
continue to gather data and identify potential
complications regarding MSC therapies.
CONCLUSION
MSCs have potential to be a widely used modality in
the next decade. New RCTs, case reports, and cohort
studies demonstrate the potential use of MSCs
in a variety of cartilage-related pathologies and
therapies. Larger RCTs are needed to identify optimal
cell sources, required cell counts for injection,
cell processing methods, and ideal supplemental
ingredients such as PRP, HA, and growth factors.
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